Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2026 11:00 ET | Source: Vishay Intertechnology, Inc.

New Vishay Intertechnology Space-Grade Common Mode Choke Provides EMI Filtering for GaN and SiC Switching Applications

MALVERN, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new space-grade, surface-mount common mode choke designed to provide EMI filtering and...
March 18, 2026 09:15 ET | Source: Fatboy

Fatboy Canada: Outdoor Living Starts Here for Spring/Summer 2026

Fatboy Canada launches its Spring/Summer collection: modular lounges, dining sets, lighting, and bean bags to create the ultimate outdoor living space.
March 18, 2026 09:00 ET | Source: Paragonix Technologies, Inc.

Paragonix Reaches 1,000 KidneyVault System Cases, Setting a New Standard in Kidney Transport

WALTHAM, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and services, today announced the completion of the 1,000th clinical case using...
March 18, 2026 08:05 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...
March 17, 2026 17:54 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates...
March 17, 2026 17:02 ET | Source: Zymeworks Inc.

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting...
March 17, 2026 16:52 ET | Source: OraSure Technologies, Inc.

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
March 17, 2026 16:52 ET | Source: Boundless Bio, Inc.

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...
March 17, 2026 16:35 ET | Source: Immuneering Corporation

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
March 17, 2026 16:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...